베나제프릴
Benazepril
Benazepril HCl
다른 이름: Fortekor · Lotensin · Benace · Boncordin · Briem · Cibacene · Labopal · Lotrel · Tensanil · Zinadril · Cardalis · Nelio · Benefortin · Benazecare · CGS-14824A · benazepril hydrochloride · Benazeprilum
VetSheet 수의사 팀 검수업데이트 2026년 4월 5일근거 기반 수의학 참고자료
감사 완료 v13 용량 근거
구조화 용량 계산 근거Adjunctive treatment of hypertrophic heart failure (extralabel)
- q12-24h
NA
반드시 함께 고려할 임상 맥락 (2)
- ■ This medicine may be given with or without food. It is usually well tolerated but vomiting and diarrhea can occur. Give with food if vomiting or lack of appetite becomes a problem.
- Benazepril tablets (and combination products) should be stored at temperatures less than 30°C (86°F) and protected from moisture.
용량은 수의사 전문가를 위한 임상 참고자료입니다. 반드시 최신 약물 정보 및 개별 환자에 따라 확인하시기 바랍니다.
개요
베나제프릴은 개와 고양이의 심부전, 전신 고혈압, 만성 신부전 및 단백상실성 신증 관리에 수의학에서 널리 사용되는 안지오텐신 전환 효소(ACE) 억제제입니다.
임상적 특징:
- 거의 전적으로 신장을 통해 배설되는 에날라프릴과 달리, 베나제프릴의 활성 대사체(베나제프릴라트)는 개에서 간(55%)과 신장(45%) 양쪽 경로를 통해 배설됩니다. 이러한 이중 배설 경로 덕분에 신기능 장애가 동반된 환자에게 더 선호되는 ACE 억제제입니다.
- 사구체 내 고혈압을 낮추는 데 특히 유익하여 만성 신장 질환에서 단백뇨를 감소시킵니다.
- (캡토프릴과 달리) 설프히드릴기가 없기 때문에 면역 매개성 부작용을 일으킬 가능성이 적습니다.
작용 기전
Benazepril is a prodrug that is hydrolyzed in the liver to its active metabolite, benazeprilat. It competitively inhibits Angiotensin-Converting Enzyme (ACE).
- Pathway: Angiotensin I → (blocked by ACE) → Angiotensin II
- Hemodynamic Effects: By preventing the formation of Angiotensin II (a potent vasoconstrictor), benazepril promotes vasodilation, reducing both preload and afterload in heart failure patients.
- Renal Effects: It dilates the efferent arterioles of the glomerulus more than the afferent arterioles, reducing intraglomerular capillary pressure and subsequently decreasing proteinuria.
- Endocrine Effects: Decreased Angiotensin II leads to reduced secretion of aldosterone from the adrenal cortex, minimizing sodium and water retention.
안전성·주의사항
금기사항
- Known hypersensitivity to ACE inhibitors
부작용
- Anorexia
- Vomiting
- Diarrhea
- Hypotension
- Renal dysfunction (worsening azotemia)
- Hyperkalemia
주의
Important Warnings:
- Use with caution in patients with hyponatremia or sodium depletion, coronary or cerebrovascular insufficiency, preexisting hematologic abnormalities, or collagen vascular diseases (e.g., SLE).
- Patients with severe congestive heart failure (CHF) should be monitored very closely upon initiation of therapy due to the risk of profound hypotension.
- ACE inhibitors can potentially worsen preexisting azotemia. It is recommended to use a lower starting dose and closely monitor BUN and creatinine.
- Pregnancy: Mildly fetotoxic at high dosages. Use during pregnancy only when potential benefits outweigh the risks to the offspring (FDA Category C in first trimester, Category D in second/third trimesters).
약물 상호작용
May potentially negate the decrease in systemic vascular resistance induced by ACE inhibitors (though low-dose aspirin may not significantly affect hemodynamics).
Possible increased risk for hypoglycemia; enhanced monitoring recommended.
Potential for increased hypotensive effects. Reducing furosemide doses by 25-50% is often recommended when initiating ACE inhibitors for heart failure.
Increased risk of hyperkalemia; enhanced monitoring of serum potassium is required.
Possible increased serum lithium levels; increased monitoring required.
Increased risk for hyperkalemia.
Potential for hyperkalemia due to additive potassium-sparing effects, though concurrent use is generally safe in practice.
Increased risk of nephrotoxicity and decreased clinical efficacy of benazepril.
Increased risk of hypotension and prerenal azotemia.
Additive hypotensive effects.
Increased risk of hypotension due to negative inotropic effects.
모니터링
- Clinical signs of Congestive Heart Failure (CHF)
- Serum electrolytes (especially potassium)
- Renal panel (Creatinine, BUN)
- Urine protein (UPC ratio)
- Blood pressure (especially if treating hypertension or if signs of hypotension arise)
약동학
반감기
흡수
Rapidly absorbed after oral dosing in healthy dogs. In humans, food apparently does not affect the extent of absorption.
분포
Crosses the placenta and is distributed into milk in very small amounts. Highly bound to serum proteins (~95% in humans).
대사
Hydrolyzed in the liver to the active metabolite, benazeprilat.
배설
In dogs, benazeprilat is cleared via both renal (45%) and hepatic (55%) routes. Mild to moderate renal dysfunction does not significantly alter elimination as biliary clearance compensates.
과다투여
In overdose situations, the primary concern is hypotension.
- Treatment: Supportive treatment with volume expansion using normal saline is recommended to correct blood pressure.
- Monitoring: Because of the drug's long duration of action, prolonged monitoring and treatment may be required.
- Decontamination: Recent massive overdoses should be managed using standard gut-emptying protocols (emesis, activated charcoal) as appropriate.
제품
제형
- Oral tablets
동물용의약품
- Benazepril Tablets: 2.5 mg, 5 mg, & 20 mg (Fortekor® - UK/POM-V)
인용의약품
- Benazepril HCl Oral Tablets: 5 mg, 10 mg, 20 mg, & 40 mg (Lotensin®, generic)
- Fixed dose combination with amlodipine (Lotrel®)
- Fixed dose combination with hydrochlorothiazide (Lotensin HCT®)
규제 현황
POM-V classification.
POM-V classification.
규제 데이터 없음: 🇺🇸 US · 🇭🇰 HK · 🇹🇼 TW · 🇯🇵 JP · 🇰🇷 KR · 🇦🇺 AU
보관·안정성
Store tablets at temperatures less than 86°F (30°C) and protect from moisture. Dispense in tight containers.
보호자 정보
- 임의 중단 금지: 수의사의 동의 없이 약물 투여를 갑자기 중단하거나 용량을 줄이지 마십시오.
- 부작용 관찰: 구토나 설사가 지속되거나 심한 경우, 또는 반려동물의 상태가 악화(예: 무기력, 쇠약, 기절)되면 즉시 수의사에게 연락하십시오.
- 투여 방법: 식사와 함께 또는 빈속에 투여할 수 있습니다. 반려동물이 항상 신선한 물을 마실 수 있도록 해주십시오.
- 정기적인 모니터링: 이 약을 복용하는 동안 반려동물의 혈압과 신장 기능을 모니터링하기 위해 정기적으로 동물병원을 방문하는 것이 매우 중요합니다.
VetSheet 의약품 참고자료는 수의사 전문가의 임상 의사결정 지원을 위한 것이며, 전문적 판단이나 제조사의 최신 약물 정보를 대체할 수 없습니다.